Poor
Not Aligned
Patient Risk:
Medium
Summary
Most evaluated claims are not supported by the provided FDA label excerpts for the specific product (methylprednisolone sodium succinate for injection, USP). Several claims are about other dosage forms (e.g., tablets, topical creams/ointments, oral suspensions, ready-to-use liquid injection) or generic inactive-ingredient examples that are not present in the supplied label text. Where label excerpts were provided (inactive ingredients for injection vial and benzyl alcohol-related precautions/contraindication), only limited portions align.
Category Scores
Accurate Statements
Methylprednisolone sodium succinate for injection, USP contains benzyl alcohol after mixing, and benzyl alcohol-related toxicity risk is discussed particularly in neonates; premature infants have a contraindication related to benzyl alcohol.
CONTRAINDICATIONS (Section 4): use is contraindicated for premature infants after mixing as directed (benzyl alcohol). WARNINGS (Section 5) and Pediatric Use: benzyl alcohol potentially toxic, particularly in neonates; gasping syndrome discussed.
Unsupported Statements
Methylprednisolone tablets commonly include inactive ingredients such as lactose monohydrate.
Provided label excerpts are for methylprednisolone sodium succinate for injection, USP and list inactive ingredients for injection vials; no tablet composition information is supplied.
Methylprednisolone tablets commonly include inactive ingredients such as corn starch.
No tablet inactive-ingredient composition is provided in the supplied label excerpts.
Methylprednisolone tablets commonly include inactive ingredients such as soybean oil.
No tablet inactive-ingredient composition is provided in the supplied label excerpts.
Methylprednisolone tablets commonly include inactive ingredients such as magnesium stearate.
No tablet inactive-ingredient composition is provided in the supplied label excerpts.
Methylprednisolone tablets may include inactive ingredients such as cellulose.
No tablet inactive-ingredient composition is provided in the supplied label excerpts.
Methylprednisolone tablets may include inactive ingredients such as gelatin.
No tablet inactive-ingredient composition is provided in the supplied label excerpts.
Methylprednisolone tablets may include inactive ingredients such as pharmaceutical glaze.
No tablet inactive-ingredient composition is provided in the supplied label excerpts.
Methylprednisolone is available in powder-for-injection and ready-to-use liquid injection forms.
The provided excerpts do not state availability of both powder-for-injection and ready-to-use liquid injection forms.
Powder-for-injection methylprednisolone requires reconstitution with a diluent before administration.
The provided label excerpt includes reconstitution details for the injection product (diluent/Bacteriostatic Water guidance) but does not support a generalized statement about “powder-for-injection” requiring reconstitution vs other available injection presentation(s). The excerpts do not confirm the specific “powder-for-injection” dosage form.
Inactive ingredients in methylprednisolone injection formulations can vary.
The provided excerpt lists specific inactive ingredients for certain vial strengths; it does not support a generalized “can vary” statement.
Inactive ingredients in methylprednisolone injection formulations may include buffering agents.
No buffering agents are identified in the supplied inactive-ingredient list; phosphates are listed but no claim about “buffering agents” is supported.
Inactive ingredients in methylprednisolone injection formulations may include preservatives.
Benzyl alcohol is listed as an excipient/preservative in context, but the claim is framed broadly as “may include preservatives” and is not specifically supported as a general class statement from the excerpt.
Inactive ingredients in methylprednisolone injection formulations may include solubilizers.
No solubilizer inactive ingredients are identified in the supplied label excerpts.
Topical methylprednisolone creams and ointments contain inactive ingredients that facilitate skin penetration.
Provided label excerpts relate to injection product; no topical cream/ointment formulations or inactive-ingredient functions are provided.
Topical methylprednisolone creams and ointments contain inactive ingredients that provide the vehicle for the active drug.
No topical product composition or excipient description is provided in the supplied label excerpts.
Topical methylprednisolone products may include emollients such as petrolatum or mineral oil.
No topical inactive-ingredient examples are provided in the supplied label excerpts.
Topical methylprednisolone products may include emulsifiers.
No topical inactive-ingredient examples are provided in the supplied label excerpts.
Topical methylprednisolone products may include preservatives.
No topical inactive-ingredient examples are provided in the supplied label excerpts.
Topical methylprednisolone products may include thickeners.
No topical inactive-ingredient examples are provided in the supplied label excerpts.
Methylprednisolone's active ingredient is methylprednisolone.
For the labeled product provided, the active ingredient is methylprednisolone sodium succinate, not “methylprednisolone” generically.
Methylprednisolone is available in formulations including tablets.
The provided label excerpts are for an injection product only; no statement of tablet availability is supported.
Methylprednisolone is available in formulations including oral suspensions.
The provided label excerpts are for an injection product only; no statement of oral suspension availability is supported.
Methylprednisolone is available in formulations including intravenous injections.
The label excerpt indicates IV use for the injection product when oral therapy is not feasible, but the claim is framed as general formulation availability; it is not supported as a broad availability statement beyond the indicated route for this injection.
Methylprednisolone is available in formulations including topical creams.
No topical formulations are described in the supplied label excerpts.
Methylprednisolone is available in formulations including topical ointments.
No topical formulations are described in the supplied label excerpts.
Methylprednisolone formulations contain inactive ingredients that help stabilize the drug.
No statement about inactive ingredients’ stabilizing function is provided in the supplied label excerpts.
Methylprednisolone formulations contain inactive ingredients that enhance absorption.
No statement about enhancing absorption is provided in the supplied label excerpts.
Methylprednisolone formulations contain inactive ingredients that provide a specific delivery mechanism.
No statement about inactive ingredients providing a “delivery mechanism” is provided in the supplied label excerpts.
Contradictions
Important Omissions
Any claim alignment with the label’s reconstitution/administration instructions for this specific injection product (e.g., “Use only Bacteriostatic Water for Injection with Benzyl Alcohol when reconstituting” and “Use within 48 hours after mixing”).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims generalize across dosage forms (tablets/topicals/oral suspensions) and broadly describe inactive-ingredient classes without support from the supplied label excerpts for the injection product. While these do not directly state a dosing instruction, unsupported composition/function claims can mislead labeling alignment and may indirectly affect safety understanding.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims reference multiple dosage forms and generic inactive-ingredient examples that are not supported by the provided FDA label excerpts for methylprednisolone sodium succinate for injection, USP; also one claim incorrectly states the active ingredient as “methylprednisolone” instead of methylprednisolone sodium succinate.
Suggested Improvement
Limit evaluation and claims to the specific labeled product and provided excerpted sections; when discussing inactive ingredients, cite only those listed in the DESCRIPTION for the injection vials, and avoid generic statements about unrelated dosage forms (tablets/topicals/oral suspensions) and unsupported excipient functions.